Neuregulin-1 prevents amyloid β-induced impairment of long-term potentiation in hippocampal slices via ErbB4

Sun Seek Min, Jihua An, Ji Hye Lee, Geun Hee Seol, Jae Hyeung Im, Hye Sun Kim, Tai Kyoung Baik, Ran Sook Woo

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Neuregulin-1 (NRG1) participates in numerous neurodevelopmental processes and plasticity of the brain. Despite this, little is known about its role in Alzheimer's disease (AD). Amyloid β (Aβ) peptide is generally believed to play a critical role in the pathogenesis of AD. The present study examined the effect of synthetic Aβ 1-42 peptides on long-term potentiation (LTP) in the CA1 region of mice hippocampal slices, a cellular model of learning and memory. We found that application of a test dose of Aβ 1-42 (200nM) significantly inhibited the development of LTP without affecting basal synaptic transmission. Pretreatment with NRG1 effectively prevented Aβ 1-42-induced impairment of LTP, an effect that was dose-dependent. This LTP-restoring action of NRG1 was almost completely abolished by blocking ErbB4, a key NRG1 receptor, suggesting that NRG1 acts through ErbB4 to exert its protective action on LTP. The present study thus provides the first demonstration that NRG1/ErbB4 protects against Aβ-induced hippocampal LTP impairment, suggesting that NRG1 may be a promising candidate for the treatment of early-stage AD.

Original languageEnglish
Pages (from-to)6-9
Number of pages4
JournalNeuroscience Letters
Volume505
Issue number1
DOIs
Publication statusPublished - 2011 Nov 7

    Fingerprint

Keywords

  • Alzheimer's disease
  • Amyloid beta peptide
  • ErbB4
  • Hippocampus
  • Long-term potentiation
  • Neuregulin

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this